Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Industry Perspective on Artificial Intelligence/Machine Learning in Pharmacovigilance

R. Kassekert, N. Grabowski, D. Lorenz, C. Schaffer, D. Kempf, P. Roy, O. Kjoersvik, G. Saldana, S. ElShal

. 2022 ; 45 (5) : 439-448. [pub] 20220517

Language English Country New Zealand

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22018539

TransCelerate reports on the results of 2019, 2020, and 2021 member company (MC) surveys on the use of intelligent automation in pharmacovigilance processes. MCs increased the number and extent of implementation of intelligent automation solutions throughout Individual Case Safety Report (ICSR) processing, especially with rule-based automations such as robotic process automation, lookups, and workflows, moving from planning to piloting to implementation over the 3 survey years. Companies remain highly interested in other technologies such as machine learning (ML) and artificial intelligence, which can deliver a human-like interpretation of data and decision making rather than just automating tasks. Intelligent automation solutions are usually used in combination with more than one technology being used simultaneously for the same ICSR process step. Challenges to implementing intelligent automation solutions include finding/having appropriate training data for ML models and the need for harmonized regulatory guidance.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018539
003      
CZ-PrNML
005      
20220804134838.0
007      
ta
008      
220720s2022 nz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s40264-022-01164-5 $2 doi
035    __
$a (PubMed)35579809
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Kassekert, Raymond $u GlaxoSmithKline, Global Safety, Upper Providence, PA, USA
245    10
$a Industry Perspective on Artificial Intelligence/Machine Learning in Pharmacovigilance / $c R. Kassekert, N. Grabowski, D. Lorenz, C. Schaffer, D. Kempf, P. Roy, O. Kjoersvik, G. Saldana, S. ElShal
520    9_
$a TransCelerate reports on the results of 2019, 2020, and 2021 member company (MC) surveys on the use of intelligent automation in pharmacovigilance processes. MCs increased the number and extent of implementation of intelligent automation solutions throughout Individual Case Safety Report (ICSR) processing, especially with rule-based automations such as robotic process automation, lookups, and workflows, moving from planning to piloting to implementation over the 3 survey years. Companies remain highly interested in other technologies such as machine learning (ML) and artificial intelligence, which can deliver a human-like interpretation of data and decision making rather than just automating tasks. Intelligent automation solutions are usually used in combination with more than one technology being used simultaneously for the same ICSR process step. Challenges to implementing intelligent automation solutions include finding/having appropriate training data for ML models and the need for harmonized regulatory guidance.
650    12
$a umělá inteligence $7 D001185
650    _2
$a automatizace $7 D001331
650    _2
$a lidé $7 D006801
650    _2
$a strojové učení $7 D000069550
650    12
$a farmakovigilance $7 D060735
650    _2
$a technologie $7 D013672
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Grabowski, Neal $u AbbVie, Pharmacovigilance and Patient Safety Business Process Office, North Chicago, IL, USA. neal.grabowski@abbvie.com $1 https://orcid.org/0000000270252508
700    1_
$a Lorenz, Denny $u Bayer AG, Medical Affairs and Pharmacovigilance, Pharmaceuticals, Berlin, Germany
700    1_
$a Schaffer, Claudia $u Merck Healthcare, Case and Vendor Management-Global Patient Safety, Darmstadt, Germany
700    1_
$a Kempf, Dieter $u Genentech, A Member of the Roche Group, South San Francisco, CA, USA
700    1_
$a Roy, Promit $u Novartis, Chief Medical Office and Patient Safety, Novartis Global Drug Development, Dublin, Ireland $u Trinity College, Dublin, Ireland
700    1_
$a Kjoersvik, Oeystein $u MSD, R&D IT, Prague, Czech Republic
700    1_
$a Saldana, Griselda $u Amgen, Pharmacovigilance Operations, Los Angeles, CA, USA
700    1_
$a ElShal, Sarah $u UCB, IT Patient Safety, Brussels, Belgium
773    0_
$w MED00001449 $t Drug safety $x 1179-1942 $g Roč. 45, č. 5 (2022), s. 439-448
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35579809 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134832 $b ABA008
999    __
$a ok $b bmc $g 1822233 $s 1169782
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 45 $c 5 $d 439-448 $e 20220517 $i 1179-1942 $m Drug safety $n Drug Saf $x MED00001449
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options